Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Down 13.0%

Shares of NASDAQ:TTNP opened at $4.55 on Monday. The company has a 50-day moving average price of $3.81 and a 200-day moving average price of $3.72. The company has a market cap of $4.16 million, a price-to-earnings ratio of -0.87 and a beta of 1.25. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.